Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.
about
RASopathies: unraveling mechanisms with animal modelsSmall G proteins in the cardiovascular system: physiological and pathological aspectsTransforming growth factor Beta2 is required for valve remodeling during heart developmentAngiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblastsMyocardial deletion of Smad4 using a novel α skeletal muscle actin Cre recombinase transgenic mouse causes misalignment of the cardiac outflow tractCalcium-mediated histone modifications regulate alternative splicing in cardiomyocytes.MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutationNeurofibromin (Nf1) is required for skeletal muscle developmentNf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferationMitofusins 1 and 2 are essential for postnatal metabolic remodeling in heartGenotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.Inhibition of farnesyl pyrophosphate synthase improves pressure overload induced chronic cardiac remodelingTargeting NF2-Hippo/Yap signaling pathway for cardioprotection after ischemia/reperfusion injuryEmerging genotype-phenotype relationships in patients with large NF1 deletions.Modeling RASopathies with Genetically Modified Mouse Models.Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms.A case report of acute myeloid leukemia and neurofibromatosis 1.
P2860
Q26800379-7666A360-8228-46B7-9095-2F44B200730DQ27010607-EE73FC80-0224-4D1A-82EB-B7CE509C6076Q28505676-85D20DD0-8710-4018-9054-DC2E0F9C1780Q28583081-6E8215D0-68CF-42D9-B0FB-CCDF7BB87C6EQ34156745-231668F2-2040-4F9C-AB6A-06EF604DE809Q34581100-EA8270FC-89E7-4951-93B1-AA910D5DB8B3Q34627221-F788E42A-19CC-4072-B3BE-2D00E20F1897Q35056040-F19086E2-47FB-470D-B259-F0B6BB161601Q35944775-5173729B-4B45-4603-8EB2-4765793BB0B5Q36455449-CAA8732D-D16F-4382-8001-990B4FC2C434Q36483309-2B1A23AF-FF44-4EB0-BCEB-15036EB1B885Q36510904-8904E241-6886-460B-AECA-DA6F225973CBQ36839960-F1941C90-2FC0-4575-A7AC-F797A2C8889EQ37529284-F7C30039-A805-426B-9699-70BF22628EBBQ37583761-4B21E76A-260E-46BB-B5E9-54E21F62E6F3Q37725901-D0897251-FDB2-48E2-9756-6E818DBA81F1Q39031139-10DEBE55-EC69-4458-ABA4-A96B1D738528Q40132696-F4CE0163-F469-4FAE-8FBD-7C426EAFBB94Q43080898-E3A6FE7C-3FD3-42D8-BC64-5DEAA8B3A02C
P2860
Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiomyocyte-specific loss of ...... c hypertrophy and dysfunction.
@en
Cardiomyocyte-specific loss of ...... c hypertrophy and dysfunction.
@nl
type
label
Cardiomyocyte-specific loss of ...... c hypertrophy and dysfunction.
@en
Cardiomyocyte-specific loss of ...... c hypertrophy and dysfunction.
@nl
prefLabel
Cardiomyocyte-specific loss of ...... c hypertrophy and dysfunction.
@en
Cardiomyocyte-specific loss of ...... c hypertrophy and dysfunction.
@nl
P2093
P2860
P1433
P1476
Cardiomyocyte-specific loss of ...... c hypertrophy and dysfunction.
@en
P2093
Fraz A Ismat
Jonathan A Epstein
Junwang Xu
Min Min Lu
Nicole Antonucci
P2860
P304
P356
10.1161/CIRCRESAHA.109.201509
P577
2009-07-02T00:00:00Z